• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Onconetix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/16/25 8:40:11 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    false 0001782107 0001782107 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 16, 2025

     

    Onconetix, Inc.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41294   83-2262816
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    201 E. Fifth Street, Suite 1900

    Cincinnati, Ohio

      45202
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (513) 620-4101

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On June 16, 2025, Onconetix, Inc. (the “Company”) issued a press release announcing that it received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with certain Nasdaq Listing Rules on or before June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K:

     

    Exhibit No.   Description
    99.1   Press Release, dated June 16, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Onconetix, Inc.
       
    June 16, 2025 By: /s/ Karina M. Fedasz
      Name: Karina M. Fedasz
      Title: Interim Chief Executive Officer and Interim Chief Financial Officer

     

    2

     

    Get the next $ONCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tarsh Simon acquired 39 shares and was granted 618 shares, increasing direct ownership by 65,700% to 658 units (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:27 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meier Thomas acquired 39 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:25 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Oakley Andrew John acquired 20 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:29 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    SEC Filings

    View All

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/26/25 8:45:57 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/22/25 8:37:50 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/4/25 4:05:41 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

    CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

    9/26/25 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

    CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

    9/26/25 8:15:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

    CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property

    9/22/25 8:00:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care